Introduction
Resistance to antimicrobial agents is a particular problem in communityacquired respiratory tract infections (CARTIs). In some countries macrolide resistance now exceeds penicillin resistance in Streptococcus pneumoniae. 1 Between 10% and 30% of Haemophilus influenzae and 85-100% of Moraxella catarrhalis worldwide are β-lactamase producers. In the UK, erythromycin A resistance in S. pneumoniae was higher than penicillin resistance by 7.7%. 1 Telithromycin is a ketolide, which represents a new generation of antimicrobial agents capable of overcoming these resistance problems. Telithromycin has activity against all three respiratory tract pathogens regardless of their resistance profiles. 2, 3 The purpose of this study was to evaluate the in vitro activity of telithromycin in comparison with a variety of antimicrobial agents against macrolide-susceptible and -resistant S. pneumoniae, M. catarrhalis and H. influenzae isolated over the same time period as the PROTEKT study, 1999-2001, from the UK. As the number of macrolide-resistant S. pneumoniae identified from the Edinburgh and Leeds collections was low, a cohort of macrolide-resistant isolates from Europe and America were also tested against telithromycin to investigate the activity of telithromycin against resistant isolates. This ensured that a diverse group of macrolide-resistant S. pneumoniae isolates were included in the study. 
Materials and methods

Bacterial strains
Antimicrobial agents
The antimicrobial agents were stored and prepared according to the manufacturers' guidelines. Telithromycin (Aventis Pharma Ltd), erythromycin (David Bull Laboratories, Warwick, UK), azithromycin (Pfizer Ltd), clindamycin (Sigma), moxifloxacin (Bayer), gemifloxacin (SmithKline Beecham Pharmaceuticals) and linezolid (Pharmacia and Upjohn) were tested in vitro.
Minimum inhibitory concentrations
The MICs were determined on Columbia agar base supplemented with 5% defibrinated horse blood for S. pneumoniae and M. catarrhalis and on chocolate Columbia agar plates for H. influenzae according to the BSAC guidelines for susceptibility testing. 4 The MICs were determined by the standard agar doubling dilution method. The MIC plates containing telithromycin were incubated in both air and 5% CO 2 , at 37°C. All other plates were incubated in air at 37°C. The MIC tests were repeated at least once for each strain.
The antimicrobial breakpoints used were those from the BSAC guidelines except for telithromycin for which the NCCLS tentative breakpoints were used. 5, 6 Resistance to the antimicrobial agents was assigned at the following MIC values: telithromycin ≥4 mg/L for S. pneumoniae and ≥16 mg/L for H. influenzae, erythromycin ≥1 mg/L, azithromycin ≥2 mg/L and clindamycin ≥1 mg/L.
Characterization of macrolide resistance mechanism
S. pneumoniae strains with an erythromycin MIC ≥ 1 mg/L or an azithromycin MIC ≥ 2 mg/L isolated from the UK and the 40 donated isolates were screened for the presence of the erm(B) and mef(A) genes. S. pneumoniae strains were emulsified in 200 µL of MilliQ water and boiled for 10 min in order to extract the total DNA. The supernatant was used as the DNA template in PCR experiments. The PCR conditions and primers for the detection of erm(B) and mef(A) genes are those described previously by Sutcliffe et al. 7 and Tait-Kamradt et al. 8 The strains were tested for both genes at the same time. The erm(B) and mef(A) primers were added to the same reaction mixture with a MgCl 2 concentration of 4 mM.
Results
Susceptibility profiles
Telithromycin had the second lowest MIC 90 of all the antimicrobial agents tested against S. pneumoniae as shown in Table 1 . The telithromycin MIC 90 was 64-fold lower than the lowest macrolide MIC 90 . While the MIC 90 of clindamycin was the same as that of telithromycin, the upper limit of the range was substantially higher. Telithromycin activity against the 40 macrolide-resistant S. pneumoniae was the same as that against the 100 UK isolates with varying macrolide susceptibilities. The range endpoint (1 mg/L) was lower than that for the UK isolates (2 mg/L) and the MIC 90 s (0.25 mg/L) were identical. Thus telithromycin activity was not affected by the macrolide resistance mechanisms of these strains. Gemifloxacin and moxifloxacin both had high activity against S. pneumoniae with their highest MICs at 0.12 and 0. 
Correlation between telithromycin and erythromycin
The correlation between telithromycin MIC and that of erythromycin and clindamycin for S. pneumoniae are detailed in Table 2 . These results indicated that the five isolates with the highest telithromycin MICs were erythromycin resistant but clindamycin susceptible. Eight of the 12 isolates with a telithromycin MIC of 0.12 mg/L were erythromycin resistant, and three of these were also clindamycin resistant. The S. pneumoniae isolates resistant to clindamycin had telithromycin MICs of 0.032-0.12 mg/L and were also erythromycin resistant.
Effect of CO 2 incubation
When the MIC plates containing telithromycin were incubated in 5% CO 2 ( 
Resistance levels
Telithromycin had the lowest resistance levels, considerably lower than either the macrolides or the lincosamide. There was no resistance to telithromycin in either S. pneumoniae, M. catarrhalis or H. influenzae using the NCCLS breakpoints (Table 3) . Using the guidelines suggested by Soussy et al., 9 i.e. telithromycin susceptibility <0.5 mg/L and resistance ≥2 mg/L, telithromycin intermediate resistance of 1 mg/L for Gram-positive bacteria, the resistance levels for S. pneumoniae increased slightly. One per cent of S. pneumoniae isolates had telithromycin intermediate resistance. In comparison, 21% of the S. pneumoniae population was erythromycin resistant and 6% were resistant to clindamycin. In M. catarrhalis the entire population were found to be clindamycin resistant while one strain was also erythromycin resistant. No resistance to telithromycin or azithromycin was observed. Erythromycin resistance was at 8% for H. influenzae, whereas azithromycin resistance was at 1%.
Mechanisms of macrolide resistance
The 21 
Discussion
Susceptibility testing of respiratory tract pathogens is often performed in a CO 2 environment to ensure that the bacteria grow to the required concentration. In a CO 2 environment the pH of the test medium decreases. Macrolide activity is adversely affected by this pH decrease. In order to investigate whether this was also true for the ketolide telithromycin, susceptibility testing was also carried out in 5% CO 2 . This study has shown that the MIC of telithromycin increased when incubated in 5% CO 2 in comparison with air incubation. Five per cent of the S. pneumoniae strains and 4% of the H. influenzae strains changed from telithromycin susceptible to nonsusceptible entirely because of the incubation conditions. The MIC 50 s and MIC 90 s of S. pneumoniae, M. catarrhalis and H. influenzae increased by one dilution when incubated in CO 2 . These results indicated that the pH of the medium also caused an increase in Telithromycin MIC (n) 0.008 (10) 1 The French guidelines recommend testing telithromycin activity against S. pneumoniae in air as well as CO 2 in order to confirm resistance for clinical characterization. However, no such recommendations were presented for H. influenzae. The results of this study suggest that telithromycin susceptibility should be tested in air for all three organisms. Therefore, the French committee need to investigate the effect of incubation in CO 2 for H. influenzae also. The latest BSAC guidelines recommend that S. pneumoniae and H. influenzae are incubated in CO 2 and M. catarrhalis is incubated in air for susceptibility testing. Under these conditions the tentative susceptibility to telithromycin point for the three organisms is <0.5 mg/L. As incubation in CO 2 has affected each of the three organisms tested in this study it would be appropriate for the BSAC to investigate this further with these and other organisms and larger populations before providing definite guidelines on telithromycin susceptibility testing and breakpoints. 11 In the Alexander Project, erythromycin resistance in S. pneumoniae from the UK was at 13.6% in 1996 and 7.2% in 1997. 12 However, this study has shown that the resistance level in Edinburgh and Leeds for the same period was 21% in S. pneumoniae. The percentage of H. influenzae resistant to erythromycin is 8%; however, none are telithromycin resistant and almost all are azithromycin susceptible.
The results of the correlation between telithromycin, erythromycin and clindamycin identified a pattern similar to that described previously by Johnson et al. 13 All the erythromycin-and clindamycinresistant isolates were susceptible to telithromycin. The telithromycin MICs for the isolates that were erythromycin resistant alone or in combination with clindamycin resistance were higher than those for the susceptible isolates. The S. pneumoniae with an erythromycin-resistant and clindamycin-susceptible phenotype were less susceptible to telithromycin than those resistant to both. The isolates with the highest telithromycin MICs were erythromycin resistant and clindamycin susceptible. Therefore, in agreement with Johnson et al. 13 telithromycin was less affected by the erm(B)-positive than by the mef(A)-positive isolates. Thus, while telithromycin can overcome both resistance mechanisms as all isolates were telithromycin susceptible, the macrolide efflux system and to a lesser extent the target methylation do reduce telithromycin activity.
Telithromycin has previously been shown to have activity against macrolide-resistant S. pneumoniae. This finding has been borne out in these results as it was tested against 61 macrolide-resistant S. pneumoniae isolates. Telithromycin had consistently lower MICs than erythromycin for all the bacteria tested. No resistance to telithromycin was found in S. pneumoniae, M. catarrhalis or H. influenzae. The 21 macrolide-resistant S. pneumoniae isolates from the UK comprised erm(B)-and mef(A)-positive isolates in a ratio of 1:2. Usually in Europe the erm(B) gene predominates and the converse is found in the USA. This study contradicts this finding in so far as there was a greater number of mef(A)-positive UK isolates than erm(B)-positive isolates. Isolates that were erythromycin and clindamycin resistant have been attributed a constitutive macrolide resistance phenotype and those that were erythromycin resistant and clindamycin susceptible an inducible macrolide resistance phenotype. 14 Therefore, the results of this study indicate that the constitutive resistance phenotype predominates in the isolates investigated in this study. Thus telithromycin has activity against inducible macrolide-resistant S. pneumoniae and also against the inducible macrolide-resistant S. pneumoniae investigated in this study. The high overall activity of telithromycin against the three respiratory pathogens and almost no resistance indicates that telithromycin has good potential for the treatment of RTIs, including those caused by macrolide-resistant strains.
